Revised Investor Presentation

Indegene filed a revised investor presentation correcting a duplicate page issue from the May 27 submission — no material change disclosed. The presentation covers FY26 results: INR 35.1Bn revenue (29.4% CAGR FY21-FY26), 19.4% adjusted EBITDA margin, 162% OCF-to-PAT ratio, and $74.7K revenue per employee. The company serves 20 of the Top 20 global pharma clients with 91 active clients (up from 44 in FY21) and 53 clients exceeding $1M in revenue. Net revenue retention remains above 100% annually. Management highlighted that the FY27 pipeline is 17% higher year-over-year with balanced strength across Top-20 and outside-Top-20 segments. The presentation frames Indegene as an AI-embedded operating partner competing for agency and CRO wallet share across commercial, medical, and regulatory workflows. The company maintains a zero-debt balance sheet.